What is ovine lactadherin and where does it come from?

Ovine lactadherin is a glycoprotein derived from the milk fat globule membrane (MFGM) of sheep (Ovis aries). It belongs to the MFG-E8 family of proteins and contains EGF-like domains and C-terminal discoidin C1/C2 domains responsible for lipid membrane binding. It is found naturally in sheep milk alongside other bioactive MFGM components such as butyrophilin and xanthine oxidase.

Does ovine lactadherin have any proven anti-thrombotic effects?

No proven anti-thrombotic effects have been established in human subjects for ovine lactadherin. The hypothesis stems from structural homology to coagulation cofactors V and VIII, and in vitro data showing that related lactadherin isoforms can compete for phosphatidylserine binding sites on platelet membranes, which are critical for prothrombinase complex assembly. These findings are preliminary and species-specific translation to humans has not been tested.

How is ovine lactadherin different from bovine lactadherin?

Ovine lactadherin (from Ovis aries) and bovine lactadherin (from Bos taurus) are orthologous MFG-E8 proteins sharing high sequence identity across their discoidin and EGF-like domains, but differ in glycosylation patterns and specific amino acid residues that may influence receptor binding affinity. Bovine lactadherin has been studied more extensively, including in murine thrombosis models, whereas ovine lactadherin lacks independent experimental characterization. These structural differences make direct extrapolation of bovine findings to the ovine form scientifically unreliable.

What receptors does ovine lactadherin bind to?

Based on structural modeling and homology to bovine MFG-E8, ovine lactadherin is predicted to interact with integrin receptors αvβ3 and αvβ5 via an RGD-containing EGF-like domain, and to bind phosphatidylserine-rich membrane surfaces through its C1 and C2 discoidin domains. These interactions are implicated in apoptotic cell clearance and platelet membrane modulation in related species. Direct receptor binding studies specific to the ovine isoform in human tissue have not been published.

Is ovine lactadherin safe to take as a supplement?

The safety of ovine lactadherin as an isolated supplement is currently unknown due to a complete absence of human toxicology or pharmacokinetic studies. Individuals with allergies to sheep milk proteins should consider it contraindicated given the risk of cross-reactive IgE-mediated responses. No established safe dosage, tolerable upper limit, or drug interaction profile exists, making its use as a standalone supplement premature from an evidence-based safety perspective.

What is the current level of clinical evidence for ovine lactadherin as a supplement?

Ovine lactadherin currently lacks any human clinical trials, making it an ingredient with primarily theoretical support rather than proven efficacy in humans. Evidence is limited to structural homology studies and in vitro research suggesting potential anti-thrombotic properties. Any health claims about ovine lactadherin supplements remain unsubstantiated by clinical research, and consumers should be aware that its safety and effectiveness have not been demonstrated in human populations.

Can ovine lactadherin be obtained through dietary sources, or is supplementation the only option?

Ovine lactadherin is naturally present in sheep milk and sheep milk-derived products, making dietary consumption possible for those consuming sheep dairy. However, the concentration and bioavailability of lactadherin from conventional food sources have not been established or compared to supplement forms. Most ovine lactadherin products on the market are concentrated supplements rather than whole food sources, which may deliver higher doses than typical dietary intake.

Who should avoid ovine lactadherin supplements based on current knowledge?

Individuals with milk protein allergies or severe lactose intolerance should exercise caution, as ovine lactadherin is derived from sheep milk proteins. People taking anticoagulant medications should consult a healthcare provider before use, given the preliminary structural evidence suggesting potential anti-thrombotic activity. Since no safety data exists for pregnant women, nursing mothers, or children, supplementation in these populations is not recommended without medical guidance.

Ovine Lactadherin (Ovis aries)

Ovine lactadherin is a milk fat globule membrane glycoprotein from sheep (Ovis aries) containing EGF-like and discoidin domains that enable phosphatidylserine binding. Its structural homology to coagulation factors V and VIII suggests potential roles in modulating thrombotic pathways, though no human clinical trials have confirmed these effects.

Category: Protein Evidence: 2/10 Tier: Emerging

Ovine Lactadherin (Ovis aries) — Hermetica Encyclopedia

Origin & History

Ovine lactadherin is a glycoprotein derived from sheep (Ovis aries) milk, specifically from milk fat globule membranes in whey or colostrum. It is extracted through standard whey processing from colostrum or milk, followed by proteomic identification techniques like mass spectrometry. The protein belongs to the chemical class of milk proteins with C2 domains exhibiting discoidin-like folds, similar to coagulation factors.

Historical & Cultural Context

No evidence of historical or traditional medicinal use for ovine lactadherin exists in any traditional medicine systems including Ayurveda or TCM. The compound has only been documented in modern proteomics and structural biology contexts without any traditional therapeutic applications.

Health Benefits

• No clinically proven health benefits - no human trials have been conducted on ovine lactadherin
• Structural homology to coagulation factors suggests potential anti-thrombotic properties (preliminary evidence only)
• May bind phosphatidylserine-containing membranes based on structural studies (no clinical evidence)
• Classified among defense/immunity proteins in proteomics studies (no therapeutic evidence)
• No evidence-based health claims can be made due to complete absence of clinical research

How It Works

Ovine lactadherin contains two C-type discoidin (C1 and C2) domains at its C-terminus that competitively bind phosphatidylserine-rich membrane surfaces, potentially displacing coagulation factors Va and VIIIa from platelet membranes and thereby attenuating thrombin generation. Its N-terminal EGF-like repeats may interact with integrin receptors, particularly αvβ3 and αvβ5, based on structural analogy to bovine lactadherin. These interactions have been characterized through in vitro binding assays and crystallographic studies, but downstream signaling consequences in human physiology remain unconfirmed.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on ovine lactadherin. Research is limited to structural studies, including crystal structure analysis of the bovine lactadherin C2 domain (PMID: 17583728) and proteomics profiling of ovine colostrum. No therapeutic efficacy, dosing, or human outcome data exists.

Clinical Summary

No human clinical trials have been conducted on ovine lactadherin as an isolated supplement ingredient. The majority of mechanistic data derives from in vitro binding studies and structural homology modeling comparing ovine sequences to the more extensively studied bovine lactadherin (MFG-E8). Bovine lactadherin has been examined in small animal models for anti-thrombotic and apoptotic cell clearance effects, but these findings cannot be directly extrapolated to the ovine isoform. The current evidence base is insufficient to support any therapeutic or health claims for ovine lactadherin in humans.

Nutritional Profile

Ovine lactadherin is a glycoprotein (also designated MFG-E8, milk fat globule-EGF factor 8) isolated from the ovine milk fat globule membrane (MFGM). As a pure protein ingredient, it contributes negligible caloric density at physiological concentrations found in milk (~0.1–0.5 mg/mL in ovine whey/MFGM fraction). Molecular weight: approximately 43–47 kDa (glycosylated form), with the polypeptide backbone contributing ~38 kDa. Contains two discoidin/F5/8 type C domains (C1 and C2) responsible for phosphatidylserine binding, and one EGF-like domain with structural homology to coagulation factors V and VIII. Amino acid composition reflects its secreted glycoprotein nature, with notable cysteine residues forming disulfide bonds critical to tertiary structure. Post-translational modifications include N-linked and O-linked glycosylation, contributing approximately 10–15% of total molecular weight as carbohydrate moieties (sialic acid, fucose, N-acetylglucosamine residues documented in bovine homolog data, extrapolated to ovine). No meaningful contribution of vitamins, minerals, or dietary fiber as an isolated protein. Bioavailability as an oral nutritional component is presumed low due to proteolytic degradation in the GI tract; intact bioactive absorption has not been measured in human or ovine feeding studies. As a minor MFGM-associated protein, it is present in ovine milk at trace levels relative to major whey proteins (casein ~80%, β-lactoglobulin, α-lactalbumin dominate), making isolated nutritional contribution essentially negligible in whole food contexts.

Preparation & Dosage

No clinically studied dosage ranges have been established for ovine lactadherin as no human trials exist. No standardized forms (extract, powder) or dosing protocols are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical research

Safety & Interactions

No formal human safety studies, toxicology profiles, or established dosing ranges exist for isolated ovine lactadherin. Individuals with sheep dairy allergies or sensitivities to ovine milk proteins face a theoretical risk of allergic reaction, including IgE-mediated responses. Because of its proposed phosphatidylserine-competitive binding activity, theoretical interactions with anticoagulant medications such as warfarin or direct oral anticoagulants cannot be ruled out. Pregnant and breastfeeding individuals should avoid supplementation given the complete absence of safety data in these populations.